Nanomedicine(s) under the Microscope

被引:701
作者
Duncan, Ruth [1 ]
Gaspar, Rogerio [2 ]
机构
[1] Ctr Invest Principe Felipe, Polymer Therapeut Lab, E-46012 Valencia, Spain
[2] Univ Lisbon, Nanomed & Drug Delivery Syst Grp, Fac Pharm, P-1649003 Lisbon, Portugal
关键词
nanomedicine; nanopharmaceutical; nanoimaging agent; theranostic; regulation; cancer; N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER-DOXORUBICIN; PEGYLATED LIPOSOMAL DOXORUBICIN; SOLUBLE SYNTHETIC-POLYMERS; OXIDE NANOPARTICLES SPIONS; IN-VIVO BIODISTRIBUTION; CARBON NANOTUBES; DRUG-DELIVERY; QUANTUM DOTS; PHASE-I; COMPLEMENT ACTIVATION;
D O I
10.1021/mp200394t
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Depending on the context, nanotechnologies developed as nanomedicines (nanosized therapeutics and imaging agents) are presented as either a remarkable technological revolution already capable of delivering new diagnostics, treatments for unmanageable diseases, and opportunities for tissue repair or highly dangerous nanoparticles, nanorobots, or nanoelectronic devices that will wreak havoc in the body. The truth lies firmly between these two extremes. Rational design of "nanomedicines" began almost half a century ago, and >40 products have completed the complex journey from lab to routine clinical use. Here we critically review both nanomedicines in clinical use and emerging nanosized drugs, drug delivery systems, imaging agents, and theranostics with unique properties that promise much for the future. Key factors relevant to the design of practical nanomedicines and the regulatory mechanisms designed to ensure safe and timely realization of healthcare benefits are discussed.
引用
收藏
页码:2101 / 2141
页数:41
相关论文
共 504 条
[31]   LIPOSOMES - THE BABRAHAM CONNECTION [J].
BANGHAM, AD .
CHEMISTRY AND PHYSICS OF LIPIDS, 1993, 64 (1-3) :275-285
[32]   LIPID BILAYERS AND BIOMEMBRANES [J].
BANGHAM, AD .
ANNUAL REVIEW OF BIOCHEMISTRY, 1972, 41 :753-+
[33]   Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo [J].
Barraud, L ;
Merle, P ;
Soma, E ;
Lefrançois, L ;
Guerret, S ;
Chevallier, M ;
Dubernet, C ;
Couvreur, P ;
Trépo, C ;
Vitvitski, L .
JOURNAL OF HEPATOLOGY, 2005, 42 (05) :736-743
[34]   BORONATED STARBURST DENDRIMER MONOCLONAL-ANTIBODY IMMUNOCONJUGATES - EVALUATION AS A POTENTIAL DELIVERY SYSTEM FOR NEUTRON-CAPTURE THERAPY [J].
BARTH, RF ;
ADAMS, DM ;
SOLOWAY, AH ;
ALAM, F ;
DARBY, MV .
BIOCONJUGATE CHEMISTRY, 1994, 5 (01) :58-66
[35]   Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors [J].
Batist, Gerald ;
Gelmon, Karen A. ;
Chi, Kim N. ;
Miller, Wilson H., Jr. ;
Chia, Stephen K. L. ;
Mayer, Lawrence D. ;
Swenson, Christine E. ;
Janoff, Andrew S. ;
Louie, Arthur C. .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :692-700
[36]  
Bean C., 1959, J. Appl. Phys, V30, pS120, DOI [DOI 10.1063/1.2185850, 10.1063/1.2185850]
[37]   LYSOSOMAL ENZYME INHIBITION BY TRYPAN BLUE - A THEORY OF TERATOGENESIS [J].
BECK, F ;
LLOYD, JB ;
GRIFFITHS, A .
SCIENCE, 1967, 157 (3793) :1180-+
[38]   Active targeting of brain tumors using nanocarriers [J].
Beduneau, Arnaud ;
Saulnier, Patrick ;
Benoit, Jean-Pierre .
BIOMATERIALS, 2007, 28 (33) :4947-4967
[39]   A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy [J].
Beer, Tomasz M. ;
Ryan, Charles ;
Alumkal, Joshi ;
Ryan, Christopher W. ;
Sun, Janine ;
Eilers, Kristine M. .
ANTI-CANCER DRUGS, 2010, 21 (04) :433-438
[40]   Short communication: Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins [J].
Bendele, A ;
Seely, J ;
Richey, C ;
Sennello, G ;
Shopp, G .
TOXICOLOGICAL SCIENCES, 1998, 42 (02) :152-157